Transdermal drug delivery systems (TDDSs) overcome the hurdle of an intact skin barrier by penetrating the skin to allow molecules through. These systems reduce side effects associated with conventional hypodermic needles. Here, we introduce novel microneedle (MN) TDDSs that enhance drug delivery by creating micron-sized pores across the skin. Many MN TDDSs designed to deliver a diverse array of therapeutics, including allergen-specific immunotherapy, skin disease treatments, and vaccines, are under pre-clinical and clinical trials. Although epicutaneous approaches are emerging as new options for treating food allergy in many clinical trials, MN TDDSs could provide a more efficient and convenient route to deliver macromolecules. Furthermore, MN TDDSs may allow for safe vaccine delivery without permanent scars. MN TDDSs are a major emerging strategy for delivering novel vaccines and treatments for diseases, including skin diseases, allergic diseases, and so on.
|Number of pages||11|
|Journal||Yonsei medical journal|
|Publication status||Published - 2022 Oct|
Bibliographical noteFunding Information:
This research was funded by a grant from the Korea Healthcare Technology R&D Project through the Korean Health Industry Development Institute (HI14C1324).
This research was funded by a grant from the Korea Health-care Technology R&D Project through the Korean Health Industry Development Institute (HI14C1324).
© Yonsei University College of Medicine 2022.
All Science Journal Classification (ASJC) codes